A special video supplement to a CME conference held during the
61st ASH Annual Meeting featuring expert comments on the
management of acute myeloid leukemia. Featuring perspectives from
Dr Daniel A Pollyea.
Choice of first-line therapy for acute myeloid leukemia (AML);
selection of patients who are fit for intensive chemotherapy
(00:00)
Perspective on the choice of hypomethylating agent (HMA) to
combine with venetoclax (04:03)
Clinical implications of the Phase III QUAZAR AML-001 study
assessing maintenance CC-486 for patients with AML in first
remission (06:46)
Potential implications of combining CC-486 with venetoclax for
AML (10:25)
Biologic rationale for the synergistic effect of venetoclax
with an HMA or low-dose cytarabine for patients with AML
(13:24)
Identifying nonresponders to venetoclax-based combination
therapy; managing the monocytic (FABM5) subgroup of AML
(17:00)
Rationale for combining venetoclax with azacitidine; optimal
duration of HMA therapy (20:13)
Monitoring bone marrow counts in patients with AML receiving
venetoclax-based therapy; role of dose interruptions in managing
cytopenias (23:32)
Effect of venetoclax-based combinations on extramedullary
disease (27:36)
Strategies to mitigate tumor lysis syndrome associated with
venetoclax-based therapy (28:38)
Perspective on the use of prophylaxis to reduce the risk of
infections associated with venetoclax (30:26)
Recommendations for hospitalization of patients with AML
receiving venetoclax-based therapies (33:07)
Use of venetoclax/HMA therapy in patients with AML and high
white blood cell counts (35:41)
Benefit with the addition of venetoclax to an HMA for patients
with AML (37:35)
Outcomes for patients with AML experiencing disease relapse on
venetoclax with an HMA; mechanisms of resistance to the venetoclax
and HMA combination (39:29)
Potential for venetoclax-based combinations for patients with
AML eligible for intensive induction chemotherapy (43:41)
Case: A woman in her mid-30s with high-risk
AML who is ineligible for induction chemotherapy achieves a
complete response with venetoclax and azacitidine (48:06)
Perspective on the potential use of venetoclax/HMA prior to
transplant (50:32)
Therapeutic approach for older patients with AML harboring FLT3
and IDH mutations (53:26)
Challenges associated with the use of venetoclax-based
combinations (56:12)
Quality-of-life impact and tolerability of venetoclax/HMA
therapy (59:16)
Emerging options for patients with AML harboring p53 mutations
(1:01:03)
Rationale for the investigation of the novel, first-in-class
small molecule APR-246 in combination with azacitidine for patients
with AML with TP53 mutations (1:03:30)
Activity and tolerability of APR-246 in AML (1:05:53)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.